Photoablation with infrared radiation
Summary by NHIP
Infrared Cardiac Photoablation
The method ablates cardiac tissue using a handheld instrument that emits infrared radiation between 800 nm and 1000 nm. Distinctive wavelengths of 915 nm or 980 nm create elongated or arcuate lesions when the curved distal tip is positioned epicardially or endocardially.
Claim Score by NHIP
Abstract
Infrared surgical photoablation instruments are disclosed for creating lesions in tissue, including cardiac tissue for treatment of arrhythmias and other diseases. The hand held instruments are especially useful in open chest or port access cardiac surgery for rapid and efficient creation of curvilinear lesions to serve as conduction blocks. Photoablative instruments are disclosed that emit radiation at a wavelength in a range from about 800 nm to about 1000 nm, and preferably emit at a wavelength in a range of about 915 nm to about 980 nm. Radiation at a wavelength of 915 nm or 980 nm is commonly preferred, in some applications, because of the optimal absorption of infrared radiation by cardiac tissue at these wavelengths.

Term
Term ended
Expired 9 September 2014, 12 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
12 claims: 2 independent, 10 dependent
- 1A method of ablating cardiac tissue, comprising:positioning a distal portion of a photoablarion instrument in proximity to a target region of cardiac tissue, the instrument having a hollow housing and a light delivering element coupled to a source of photoablative radiation and disposed within the distal portions the distal portion being transmissive to ablative infrared radiation to permit the distribution of radiation by the light delivering clement in a pattern;activating the light delivering element to transmit infrared radiant energy at a wavelength ranging from about 800 nm to about 1000 nm through the hollow housing to expose the target region.
- 12Broadest claimClaim Score 80, broad(NHIP)A method of treating cardiac arrhythmias, comprising:positioning an ablation instrument in proximity to a target cardiac treatment site, the instrument including a source of penetrating energy;and activating the instrument to transmit penetrating energy at a wavelength ranging from about 800 nm to about 1000 nm into tissue at the target site to form a lesion by uniform beating of the target tissue.
Independent claims2
87 paragraphs in 5 sections, as filed
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of U.S. patent application Ser. No. 09/616,777, filed on Jul. 14, 2000 and a continuation-in-part of U.S. patent application Ser. No. 09/390,964, filed Sep. 7, 1999, now U.S. Pat. No. 6,270,492 which is a continuation-in-part of U.S. patent application Ser. No. 08/991,130, filed Dec. 16, 1997, now U.S. Pat. No. 5,947,959 which is a continuation-in-part of U.S. patent application Ser. No. 08/827,631, filed Apr. 10, 1997, now U.S. Pat. No. 5,908,415 which is a continuation-in-part of U.S. patent application Ser. No. 08/303,605, filed Sep. 9, 1994 now abandoned. This application is also a continuation-in-part of International Patent Application No. PCT/US01/22299 filed Jul. 16, 2001.
BACKGROUND OF THE INVENTION
The present invention relates to surgical ablation instruments for ablation of tissue for the treatment of diseases, and, in particular, to surgical instruments employing penetrating energy. Methods of ablating tissue using penetrating energy are also disclosed. The instruments can be used, for example, in the treatment of cardiac conditions such as cardiac arrhythmias.
Cardiac arrhythmias, e.g., fibrillation, are irregularities in the normal beating pattern of the heart and can originate in either the atria or the ventricles. For example, atrial fibrillation is a form of arrhythmia characterized by rapid randomized contractions of the atrial myocardium, causing an irregular, often rapid ventricular rate. The regular pumping function of the atria is replaced by a disorganized, ineffective quivering as a result of chaotic conduction of electrical signals through the upper chambers of the heart. Atrial fibrillation is often associated with other forms of cardiovascular disease, including congestive heart failure, rheumatic heart disease, coronary artery disease, left ventricular hypertrophy, cardiomyopathy or hypertension.
Various surgical techniques have been proposed for the treatment of arrhythmia. Although these procedures were originally performed with a scalpel, these techniques may also use ablation (also referred to as coagulation) wherein the tissue is treated, generally with heat or cold, to cause tissue necrosis (i.e., cell destruction). The destroyed muscle cells are replaced with scar tissue which cannot conduct normal electrical activity within the heart.
For example, the pulmonary vein has been identified as one of the origins of errant electrical signals responsible for triggering atrial fibrillation. In one known approach, circumferential ablation of tissue within the pulmonary veins or at the ostia of such veins has been practiced to treat atrial fibrillation. Similarly, ablation of the region surrounding the pulmonary veins as a group has also been proposed. By ablating the heart tissue (typically in the form linear or curved lesions) at selected locations, electrical conductivity from one segment to another can be blocked and the resulting segments become too small to sustain the fibrillatory process on their own. Ablation procedures are often performed during coronary artery bypass and mitral valve replacement operations because of a heightened risk of arrhythmias in such patients and the opportunity that such surgery presents for direct access to the heart.
Several types of ablation devices have recently been proposed for creating lesions to treat cardiac arrhythmias, including devices which employ electrical current (e.g., radio-frequency “RF”) heating or cryogenic cooling. Such ablation devices have been proposed to create elongated lesions that extend through a sufficient thickness of the myocardium to block electrical conduction.
These devices, however, are not without their drawbacks. When cardiac surgery is performed “on pump,” the amount of time necessary to form a lesion becomes a critical factor. Because these devices rely upon resistive and conductive heating (or cooling), they must be placed in direct contact with the heart and such contact must be maintained for a considerable period of time to form a lesion that extends through the entire thickness of the heart muscle. The total length of time to form the necessary lesions can be excessive. This is particularly problematic for procedures that are performed upon a “beating heart” patient. In such cases the heart, itself, continues to beat and, hence, is filled with blood, thus providing a heat sink (or reservoir) that works against conductive and/or resistive ablation devices. As “beating heart” procedures become more commonplace (in order to avoid the problems associated with arresting a patient's heart and placing the patient on a pump), the need for better ablation devices will continue to grow.
Moreover, devices that rely upon resistive or conductive heat transfer can be prone to serious post-operative complications. In order to quickly perform an ablation with such “contact” devices, a significant amount of energy must be applied directly to the target tissue site. In order to achieve transmural penetration, the surface that is contacted will experience a greater degree of heating (or freezing). For example, in RF heating of the heart wall, a transmural lesion requires that the tissue temperature be raised to about 50° C. throughout the thickness of the wall. To achieve this, the contact surface will typically be raised to at least 80° C. Charring of the surface of the heart tissue can lead to the creation of blood clots on the surface which can lead to post-operative complications, including stroke. Even if structural damage is avoided, the extent of the lesion (i.e., the width of the ablated zone) on the surface that has been contacted will typically be greater than necessary.
Ablation devices that do not require direct contact have also been proposed, including acoustic and radiant energy. Acoustic energy (e.g., ultrasound) is poorly transmitted into tissue (unless a coupling fluid is interposed). Laser energy has also been proposed but only in the context of devices that focus light into spots or other patterns. When the light energy is delivered in the form of a focused spot, the process is inherently time consuming because of the need to expose numerous spots to form a continuous linear or curved lesion.
In addition, existing instruments for cardiac ablation also suffer from a variety of design limitations. The shape of the heart muscle adds to the difficulty in accessing cardiac structures, such as the pulmonary veins on the anterior surface of the heart.
Accordingly, there exists a need for better surgical ablation instruments that can form lesions with minimal overheating and/or damage to collateral tissue. Moreover, instruments that are capable of creating lesions uniformly, rapidly and efficiently would satisfy a significant need in the art.
SUMMARY OF THE INVENTION
Surgical ablation instruments are disclosed for creating lesions in tissue, especially cardiac tissue for treatment of arrhythmias and the like. The hand held instruments are especially useful in open chest or port access cardiac surgery for rapid and efficient creation of curvilinear lesions to serve as conduction blocks. The instruments can be applied to form either endocardial or epicardial ablations, and are designed to create lesions in the atrial tissue in order to electrically decouple tissue segments on opposite sides of the lesion.
It has been discovered that infrared radiation is particularly useful in forming photoablative lesions. In one preferred embodiment the instruments emit radiation at a wavelength in a range from about 800 nm to about 1000 nm, and preferably emit at a wavelength in a range of about 915 nm to about 980 nm. Radiation at a wavelength of 915 nm or 980 nm is commonly preferred, in some applications, because of the optimal absorption of infrared radiation by cardiac tissue at these wavelengths. In the case of ablative radiation that is directed towards the epicardial surface, light at a wavelength about 915 nm can be particularly preferably.
In one aspect of the invention, hand-held and percutaneous instruments are disclosed that can achieve rapid and effective photoablation through the use of penetrating radiation, especially distributed radiant energy. It has been discovered that penetrating energy, e.g., microwave or diffused infrared radiation, can create lesions in less time and with less risk of the adverse types of tissue destruction commonly associated with prior art approaches. Unlike instruments that rely on thermal conduction or resistive heating, controlled penetrating radiant energy can be used to simultaneously deposit energy throughout the full thickness of a target tissue, such as a heart wall, even when the heart is filled with blood. Distributed radiant energy can also produce better defined and more uniform lesions.
In another aspect of the invention, surgical ablation instruments are disclosed that are well adapted for use in or around the intricate structures of the heart. In one embodiment, the distal end of the instrument can have a malleable shape so as to conform to the surgical space in which the instrument is used. Optionally, the distal end of the instrument can be shaped into a curve having a radius between about 5 and 25 mm. The instruments can include at least one malleable strip element disposed within the distal end of the instrument body or housing so that the distal end can be conformed into a desired shape. In addition, the instruments can also include a clasp to form a closed loop after encircling a target site, such as the pulmonary veins. Such instruments can be used not only with penetrating energy devices but also with other ablation means, such as RF heating, cryogenic cooling, ultrasound, microwave, ablative fluid injection and the like.
In yet another aspect of the invention, surgical ablation instruments are disclosed having a housing with at least one lumen therein and having a distal portion that is at least partially transmissive to photoablative radiation. The instruments further include a light delivery element within the lumen of the housing that is adapted to receive radiation from a source and deliver radiant energy through a transmissive region of the housing to a target tissue site. The radiant energy is delivered without the need for contact between the light emitting element and the target tissue because the instruments of the present invention do not rely upon conductive or resistive heating.
The light delivering element can be a light transmitting optical fiber adapted to receive ablative radiation from a radiation source and a light emitting tip at a distal end of the fiber for emitting diffuse or defocused radiation. The light delivering element can be slidably disposed within the inner lumen of the housing and the instrument can further include a translatory mechanism for disposing the tip of the light delivering element at one or more of a plurality of locations with the housing. Optionally, a lubricating fluid can be disposable between the light delivery element and the housing. This fluid can be a physiologically compatible fluid, such as saline, and the fluid can also be used for cooling the light emitting element or for irrigation via one or more exit ports in the housing.
The light emitting tip can include a hollow tube having a proximal end joined to the light transmitting optical fiber, a closed distal end, and an inner space defining a chamber therebetween. The light scattering medium disposed within the chamber can be a polymeric or liquid material having light scattering particles, such as alumina, silica, or titania compounds or mixtures thereof, incorporated therein. The distal end of the tube can include a reflective end and, optionally, the scattering medium and the reflective end can interact to provide a substantially uniform axial distribution of radiation over the length of the housing.
Alternatively, the light emitting tip can include at least one reflector for directing the radiation through the transmissive region of the housing toward a target site and, optionally can further include a plurality of reflectors and/or at least one defocusing lens for distributing the radiation in an elongated pattern.
The light emitting tip can further include at least one longitudinal reflector or similar optical element such that the radiation distributed by the tip is confined to a desired angular distribution.
The hand held instruments can include a handle incorporated into the housing. An inner lumen can extend through the handle to received the light delivering element. The distal end of the instrument can be resiliently deformable or malleable to allow the shape of the ablation element to be adjusted based on the intended use.
In one embodiment, a hand held cardiac ablation instrument is provided having a housing with a curved shape and at least one lumen therein. A light delivering element is disposable within the lumen of the housing for delivering ablative radiation to form a curved lesion at a target tissue site adjacent to the housing.
In another aspect of the invention, the light delivering element can be slidably disposed within the inner lumen of the housing, and can include a light transmitting optical fiber adapted to receive ablative radiation from a radiation source and a light diffusing tip at a distal end of the fiber for emitting radiation. The instrument can optionally include a handle joined to the housing and having an inner lumen though which the light delivering element can pass from the radiation source to the housing.
In another aspect of the present invention, the light diffusing tip can include a tube having a proximal end mated to the light transmitting optical fiber, a closed distal end, and an inner chamber defined therebetween. A light scattering medium is disposed within the inner chamber of the tube. The distal end of the tube can include a reflective end surface, such as a mirror or gold coated surface. The tube can also include a curved, longitudinally-extending, reflector that directs the radiant energy towards the target ablation site. The reflective surfaces and the light scattering medium interact to provide a substantially uniform axial distribution of radiation of the length of the housing.
In other aspects of the present invention, a hand held cardiac ablation instrument is provided having a slidably disposed light transmitting optical fiber, a housing in the shape of an open loop and having a first end adapted to receive the slidably disposed light transmitting optical fiber, and at least one diffuser chamber coupled to the fiber and disposed within the housing. The diffuser chamber can include a light scattering medium disposed within the housing and coupled to the slidably disposed light transmitting optical fiber.
In yet another aspect, a percutaneous cardiac ablation instrument in the form of a balloon catheter with an ablative light projecting assembly is provided. The balloon catheter instrument can include at least one expandable membrane disposed about a housing. This membrane is generally or substantially sealed and serves as a balloon to position the device within a lumen. The balloon structure, when filled with fluid, expands and is engaged in contact with the tissue. The expanded balloon thus defines a staging from which to project ablative radiation in accordance with the invention. The instrument can also include an irrigation mechanism for delivery of fluid at the treatment site. In one embodiment, irrigation is provided by a sheath, partially disposed about the occluding inner balloon, and provides irrigation at a treatment site (e.g. so that blood can be cleared from an ablation site). The entire structure can be deflated by applying a vacuum which removes the fluid from the inner balloon. Once fully deflated, the housing can be easily removed from the body lumen.
The present invention also provides methods for ablating tissue. One method of ablating tissue comprises positioning a distal end of a penetrating energy instrument in proximity to a target region of tissue, the instrument including a source of penetrating energy disposed within the distal end. The distal end of the instrument can be curved to permit the distribution of penetrating energy in elongated and/or arcuate patterns. The method further including activating the energy element to transmit penetrating energy to expose the target region and induce a lesion; and, optionally, repeating the steps of positioning and exposing until a composite lesion of a desired shape is formed.
In another method, a device is provided having a light delivering element coupled to a source of photoablative radiation and configured in a curved shape to emit an arcuate pattern of radiation. The device is positioned in proximity to a target region of cardiac tissue, and applied to induce a curvilinear lesion. The device is then moved to the second position and reapplied to induce a second curvilinear lesion. The steps of positioning and reapplying can be repeated until the lesions are joined together to create a composite lesion (e.g., a closed loop encircling one or more cardiac structures).
In another embodiment, methods of ablating cardiac tissue are provided. A device is provided having a housing in the shape of a hollow ring or partial ring having at least one lumen therein and at least one open end, and a light delivering element slidably disposed within the lumen of the housing for delivering ablative radiation to form a circular lesion at a target region adjacent the housing. The methods includes the steps of positioning the device in proximity to the target region of cardiac tissue, applying the device to the target region to induce a curvilinear lesion, advancing the light delivering element to a second position, reapplying the device to the target region to induce a second curvilinear lesion, and repeating the steps of advancing and applying until the lesions are joined together to create a composite circumferential lesion.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which like reference numerals designate like parts throughout the figures, and wherein:
FIG. 1 is a schematic, perspective view of a hand held surgical ablation instrument in accordance with this invention;
FIG. 1A is a partially cross-sectional view of the hand held surgical ablation instrument of FIG. 1;
FIG. 2 is a schematic, perspective view of another embodiment of a hand held surgical ablation instrument in accordance with this invention;
FIG. 2A is a partially cross-sectional view of the hand held surgical ablation instrument of FIG. 2;
FIG. 3 is a schematic, side perspective view of a tip portion of an ablation instrument in accordance with this invention illustrating a light delivery element;
FIG. 3A is a schematic, side perspective view of a tip portion of another ablation instrument in accordance with this invention;
FIG. 4 is a schematic, cross sectional view of the light delivery element of FIG. 3;
FIG. 4A is a schematic, cross sectional view of another embodiment of a light delivery element;
FIG. 4B is a schematic, cross sectional view of another embodiment of a light delivery element surrounded by a malleable housing;
FIG. 5 is a schematic, cross sectional top view of a surgical ablation element of according to the invention, illustrating the different ablating positions of the light delivering element;
FIG. 6 is a schematic, perspective view of a human heart and an instrument according to the invention, showing one technique for creating epicardial lesions;
FIG. 7 is a schematic, perspective view of a human heart and an instrument according to the invention, showing one technique for creating endocardial lesions;
FIG. 8 is a schematic, perspective view of a human heart and an instrument according to the invention, showing another technique for creating endocardial lesions;
FIG. 9 is a schematic, cross-sectional view of a balloon catheter apparatus having an irrigation sheath according to the invention;
FIG. 10 is a more detailed schematic side view of the balloon catheter apparatus of FIG. 9;
FIG. 11 shows another balloon catheter apparatus according to the invention having conduits for providing inflation fluid, and irrigation fluid to the apparatus;
FIG. 12 shows another embodiment of the balloon catheter apparatus according to the invention having pores for providing irrigation fluid to a treatment site; and
FIG. 13 shows another embodiment of the balloon catheter apparatus according to the invention having a sheath positioned to deliver fluid to a target ablation site.
DETAILED DESCRIPTION
The present invention provides a hand held ablation instrument that is useful, for example, for treating patients with atrial arrhythmia. As shown in FIG. 1, the hand held ablation instrument <b>10</b> generally includes a handle <b>12</b> having a proximal end <b>14</b> and a distal end <b>16</b>, an ablation element <b>20</b> mated to or extending distally from the distal end <b>16</b> of the handle <b>12</b>, and a laser energy source <b>50</b>. The laser energy source <b>50</b> employs the use of electromagnetic radiation, e.g., coherent light, which can be efficiently and uniformly distributed to the target site while avoiding harm or damage to surrounding tissue. In one use, the instrument can be used for cardiac ablation and can be applied either endocardially or epicardially, and is effective to uniformly irradiate a target ablation site.
The handle <b>12</b> of the ablation instrument <b>10</b> is effective for manually placing the ablation element <b>20</b> proximate to a target tissue site. While the handle <b>12</b> can have a variety of shapes and sizes, preferably the handle is generally elongate with at least one inner lumen extending therethrough. The proximal end <b>14</b> of the handle <b>12</b> is adapted for coupling with a source of phototherapeutic radiation, e.g., an infrared laser energy source <b>50</b>, and the distal end of the handle <b>16</b> is mated to or formed integrally with the ablation element <b>20</b>. In a preferred embodiment, the handle <b>12</b> is positioned substantially coaxial with the center of the ablation element <b>20</b>. The handle <b>14</b> can optionally include an on-off switch <b>18</b> for activating the laser energy source <b>50</b>.
One circumferential ablation element <b>20</b> is shown in more detail in FIG. 1A, and includes an outer housing <b>22</b> having an inner lumen extending therethrough, and a light delivering element <b>32</b> disposed within the inner lumen of the outer housing <b>22</b>. The outer housing <b>22</b> can be flexible, and is preferably malleable to allow the shape of the outer housing <b>22</b> to be adapted based on the intended use. As shown in FIG. 2, the outer housing <b>22</b> can be in the shape of a hollow ring (or partial ring) forming an opening loop having leading and trailing ends <b>24</b>, <b>26</b>. The open loop-shape allows the circumferential ablation element <b>20</b> to be positioned around one or more pulmonary veins. While an open loop shape is illustrated, the outer housing <b>22</b> can also be formed or positioned to create linear or other shaped lesions.
The housing can be made from a variety of materials including polymeric, electrically nonconductive material, like polyethylene or polyurethane, which can withstand tissue coagulation temperatures without melting. Preferably, the housing is made of Teflon® tubes and/or coatings. The use of Teflon® improves the procedures by avoiding the problem of fusion or contact-adhesion between the ablation element <b>12</b> and the cardiac tissue during usage. While the use of Teflon® avoids the problem of fusion or contact-adhesion, the hand held cardiac ablation instrument <b>10</b> does not require direct contact with the tissue to effect a therapeutic or prophylactic treatment.
The outer housing <b>22</b> can optionally include a connecting element for forming a closed-loop circumferential ablation element <b>20</b>. By non-limiting example, FIG. 1A illustrates a connecting element <b>30</b> extending from the leading, distal end <b>24</b> of the outer housing <b>22</b>. The connecting element <b>30</b> has a substantially u-shape and is adapted for mating with the trailing end <b>26</b> of the outer housing <b>22</b> or the distal end <b>16</b> of the handle <b>12</b>. The connecting element <b>30</b> can optionally be adapted to allow the size of the circumferential ablation element <b>20</b> to be adjusted once positioned around the pulmonary veins. For example, the connecting element <b>30</b> can be positioned around the trailing end <b>26</b> of the outer housing <b>22</b> after the circumferential ablation element <b>20</b> is looped around the pulmonary veins, and the handle <b>12</b> can then be pulled to cause the ablation element <b>20</b> to tighten around the pulmonary veins. While FIG. 1A illustrates a U-shaped connecting element, a person having ordinary skill in the art will appreciate that a variety of different connecting elements or clasps <b>30</b> can be used such as, for example, a hook, a cord, a snap, or other similar connecting device.
The light delivering element <b>32</b> which is disposed within the outer housing <b>22</b> includes a light transmitting optical fiber <b>34</b> and a light diffusing tip <b>36</b>. The light transmitting optical fiber <b>34</b> is effective for delivering radiant energy from the laser energy source <b>50</b> to the light diffusing tip <b>36</b>, wherein the laser energy is diffused throughout the tip <b>36</b> and delivered to the target ablation site. The light delivering element <b>32</b> can be slidably disposed within the outer housing to allow the light diffusing tip <b>36</b> to be positioned with respect to the target ablation site. A lever <b>52</b> or similar mechanism can be provided for slidably moving the light delivering element <b>32</b> with respect to the handle <b>12</b>. As shown in FIG. 1A, the lever <b>52</b> can be mated to the light delivering element <b>32</b> and can protrude from a distally extending slot <b>54</b> formed in the handle <b>12</b>. Markings can also be provided on the handle for determining the distance moved and the length of the lesion formed. A person having ordinary skill in the art will readily appreciate that a variety of different mechanisms can be employed to slidably move the light delivering element <b>32</b> with respect to the handle <b>12</b>.
Another embodiment of the surgical ablation instrument <b>10</b>A is shown in FIG. 2, where a rotatable lever <b>82</b> can be used to control the positioning of a light delivery element in the distal tip of the instrument. The lever <b>82</b> turns a translatory mechanism <b>80</b>, as shown in more detail in FIG. <b>2</b>A. In this embodiment, a portion <b>84</b> of the handle is separated from the rest of the housing <b>88</b> such that it can rotate, and preferably sealed by O-rings <b>90</b> and <b>91</b>, or the like. The rotatable segment <b>84</b> has internal screw threads <b>92</b>. Within this segment of the handle, the light delivering fiber <b>32</b> is joined to a jacket <b>93</b> that has an external screw thread <b>94</b>. The threads <b>94</b> of jacket <b>93</b> mate with the threads <b>92</b> of rotatable segment <b>84</b>. The lever <b>82</b> is affixed to rotatable segment <b>84</b> (e.g., by set screw <b>86</b>) such that rotation of knob <b>82</b> causes longitudinal movement of the fiber <b>32</b> relative to the housing <b>88</b>.
The inner lumen of the outer housing <b>22</b> in FIGS. 1 and 2 can optionally contain a lubricating and/or irrigating fluid to assist the light delivering element <b>32</b> as it is slidably movable within the outer housing <b>22</b>. The fluid can also cool the light delivering element <b>32</b> during delivery of ablative energy. Fluid can be introduced using techniques known in the art, but is preferably introduced through a port and lumen formed in the handle. The distal end <b>24</b> of the outer housing <b>22</b> can include a fluid outflow port <b>28</b> for allowing fluid to flow therethrough.
As shown in FIG. 3, the fluid travels between the light delivering element <b>32</b> toward the leading, distal end <b>26</b> of the outer housing <b>22</b> and exits the fluid outflow port <b>28</b>. Since the port <b>28</b> is positioned on the distal end <b>26</b> of the outer housing <b>22</b>, the fluid does not interfere with the ablation procedure. Suitable cooling and/or lubricating fluids include, for example, water and silicone. While FIG. 3 illustrates the fluid outflow port <b>28</b> disposed on the distal end <b>24</b> of the outer housing <b>22</b>, a person having ordinary skill in the art will readily appreciate that the fluid outflow port <b>28</b> can be disposed anywhere along the length of the outer housing <b>22</b>.
In FIG. 3A another embodiment of a light delivery element according to the invention is shown in fiber <b>34</b> terminates in a series of partially reflective elements <b>35</b>A-<b>35</b>G. (It should be appreciated that the number of reflective elements can vary depending on the application and the choice of six is merely for illustration.) The transmissivity of the various segments can controlled such that, for example, segment <b>35</b>A is less reflective than segment <b>35</b>B, which in turn is less reflective than <b>35</b>C, etc., in order to achieve uniform diffusion of the light. The reflective elements of FIG. 3A can also be replaced, or augmented, by a series of light scattering elements having similar progressive properties. FIG. 3A also illustrates another arrangement of exit ports <b>28</b> in housing <b>22</b> for fluid, whereby the fluid can be used to irrigate the target site.
With reference again to FIG. 3, the light transmitting optical fiber <b>34</b> generally includes an optically transmissive core surrounded by a cladding and a buffer coating (not shown). The optical fiber <b>34</b> should be flexible to allow the fiber <b>34</b> to be slidably moved with respect to the handle <b>12</b>. In use, the light transmitting optical fiber <b>34</b> conducts light energy in the form of ultraviolet light, infrared radiation, or coherent light, e.g., laser light. The fiber <b>34</b> can be formed from glass, quartz, polymeric materials, or other similar materials which conduct light energy.
The light diffusing tip <b>36</b> extends distally from the optical fiber <b>34</b> and is formed from a transmissive tube <b>38</b> having a light scattering medium <b>40</b> disposed therein. For additional details on construction of light diffusing elements, see, for example, U.S. Pat. No. 5,908,415 issued Jun. 1, 1999.
The scattering medium <b>40</b> disposed within the light diffusing tip <b>36</b> can be formed from a variety of materials, and preferably includes light scattering particles. The refractive index of the scattering medium <b>40</b> is preferably greater than the refractive index of the housing <b>22</b>. In use, light propagating through the optical fiber <b>34</b> is transmitted through the light diffusing tip <b>36</b> into the scattering medium <b>40</b>. The light is scattered in a cylindrical pattern along the length of the light diffusing tip <b>36</b> and, each time the light encounters a scattering particle, it is deflected. At some point, the net deflection exceeds the critical angle for internal reflection at the interface between the housing <b>22</b> and the scattering medium <b>40</b>, and the light exits the housing <b>22</b> to ablate the tissue.
Preferred scattering medium <b>40</b> includes polymeric material, such as silicone, epoxy, or other suitable liquids. The light scattering particles can be formed from, for example, alumina, silica, or titania compounds, or mixtures thereof. Preferably, the light diffusing tip <b>36</b> is completely filled with the scattering medium <b>40</b> to avoid entrapment of air bubbles.
As shown in more detail in FIG. 3, the light diffusing tip <b>36</b> can optionally include a reflective end <b>42</b> and/or a reflective coating <b>44</b> extending along a length of one side of the light diffusing tip <b>36</b> such that the coating is substantially diametrically opposed to the target ablation site. The reflective end <b>42</b> and the reflective coating <b>44</b> interact to provide a substantially uniform distribution of light throughout the light diffusing tip <b>36</b>. The reflective end <b>42</b> and the reflective coating <b>44</b> can be formed from, for example, a mirror or gold coated surface. While FIG. 3 illustrates the coating extending along one side of the length of the diffusing tip <b>36</b>, a person having ordinary skill in the art will appreciate that the light diffusing tip <b>36</b> can be coated at different locations relative to the target ablation site. For example, the reflective coating <b>44</b> can be applied over 50% of the entire diameter of the light diffusing tip <b>36</b> to concentrate the reflected light toward a particular target tissue site, thereby forming a lesion having a relatively narrow width.
In use, the hand held ablation instrument <b>10</b> is coupled to a source of phototherapeutic radiation <b>50</b> and positioned within a patient's body to ablate the tissue. The radiation source is activated to transmit light through the optical fiber <b>34</b> to the light diffusing tip <b>36</b>, wherein the light is scattered in a circular pattern along the length of the tip <b>36</b>. The tube <b>38</b> and the reflective end <b>42</b> interact to provide a substantially uniform distribution of light throughout the tip <b>36</b>. When a mirrored end cap <b>42</b> is employed, light propagating through the light diffusing tip <b>36</b> will be at least partially scattered before it reaches the mirror <b>42</b>. When the light reaches the mirror <b>42</b>, it is then reflected by the mirror <b>42</b> and returned through the tip <b>36</b>. During the second pass, the remaining radiation encounters the scattering medium <b>40</b> which provides further diffusion of the light.
When a reflective coating or longitudinally disposed reflector <b>44</b> is used, as illustrated in FIG. 4, the light <b>58</b> emitted by the diffusing tip <b>36</b> will reflected toward the target ablation site <b>56</b> to ensure that a uniform lesion <b>48</b> is created. The reflective coating or element <b>44</b> is particularly effective to focus or direct the light <b>58</b> toward the target ablation site <b>56</b>, thereby preventing the light <b>58</b> from passing through the housing <b>22</b> around the entire circumference of the housing <b>22</b>.
In another embodiment as illustrated in FIG. 4A, the light emitting element can further include a longitudinally extended lens element <b>45</b>, such that light scattered by the scattering medium <b>40</b> is not only reflected by reflector <b>44</b> but also confined to a narrow angle.
In yet another embodiment of the invention, illustrated in FIG. 4B, the housing <b>22</b> that surrounds the light delivery element that include or surround a malleable element <b>47</b>, e.g., a soft metal bar or strip such that the clinician can form the distal end of the instrument into a desired shape prior to use. Although the malleable element <b>47</b> is shown embedded in the housing <b>22</b>, it should be clear that it can also be incorporated into the light delivery element (e.g., as part of the longitudinally extended reflector) or be distinct from both the housing and the light emitter.
Epicardial ablation is typically performed during a by-pass procedure, which involves opening the patient's chest cavity to access the heart. The heart can be arrested and placed on a by-pass machine, or the procedure can be performed on a beating heart. The hand held ablation instrument <b>10</b> is placed around one or more pulmonary veins, and is preferably placed around all four pulmonary veins. The connecting element <b>30</b> can then be attached to the distal end <b>16</b> of the handle <b>12</b> or the proximal, trailing end <b>24</b> of the outer housing <b>22</b> to close the open loop. The handle <b>12</b> can optionally be pulled to tighten the ablation element <b>20</b> around the pulmonary veins. The light delivering element <b>32</b> is then moved to a first position, as shown in FIG. 5, and the laser energy source <b>50</b> is activated to transmit light. The first lesion is preferably about 4 cm in length, as determined by the length of the light diffusing tip <b>36</b>. Since the distance around the pulmonary veins is about 10 cm, the light delivering element <b>32</b> is moved forward about 4 cm to a second position <b>60</b>, shown in phantom in FIG. 5, and the tissue is ablated to create a second lesion. The procedure is repeated two more times, positioning the light delivering element <b>32</b> in a third position <b>62</b> and a fourth position <b>64</b>. The four lesions together can form a lesion <b>48</b> around the pulmonary veins, for example.
In another aspect of the invention, the instruments of the present invention are particularly useful in forming lesions around the pulmonary veins by directing radiation towards the epicardial surface of the heart and the loop configuration of distal end portion of the instruments facilitates such use. It has been known for some time that pulmonary veins can be the source of errant electrical signals and various clinicians have proposed forming conduction blocks by encircling one or more of the pulmonary veins with lesions. As shown in FIG. 6, the instrument <b>10</b> of the present invention is well suited for such ablation procedures. Because the pulmonary veins are located at the anterior of the heart muscle, they are difficult to access, even during open chest surgery. An open loop distal end is thus provided to encircle the pulmonary veins. The open loop can then be closed (or cinched tight) by a clasp, as shown. (The clasp can also take the form of suture and the distal end of the instrument can include one or more holes to receive such sutures as shown in FIG. 2.) The longitudinal reflector structures described above also facilitate such epicardial procedures by ensuring that the light from the light emitting element is directed towards the heart and not towards the lungs or other adjacent structures.
Endocardial applications, on the other hand, are typically performed during a valve replacement procedure which involves opening the chest to expose the heart muscle. The valve is first removed, and then the hand held cardiac ablation instrument <b>10</b> according to the present invention is positioned inside the heart as shown in FIG. <b>7</b>. In another approach the instrument <b>10</b> can be inserted through an access port as shown in FIG. <b>8</b>. The ablation element <b>20</b> can be shaped to form the desired lesion, and then positioned at the atrial wall around the ostia of one or more of the pulmonary veins. Once shaped and positioned, the laser energy source <b>50</b> is activated to ablate a first portion of tissue. The light delivering element <b>32</b> can then be slidably moved, as described above with respect to the epicardial application, or alternatively, the entire device can be rotated to a second position to form a second lesion.
In yet another embodiment of the present invention illustrated in FIG. 9, a balloon catheter <b>150</b> for cardiac ablation is shown having a primary balloon member <b>156</b> disposed about a housing, e.g. a catheter <b>114</b>, for inflation (via port <b>123</b>) within the body (e.g., with the heart) to provide a transmission waveguide for projecting radiation <b>113</b> to the ablation site <b>112</b>. The primary balloon member <b>156</b> is generally or substantially sealed and can be inflated to position the catheter <b>114</b> within a lumen. The catheter <b>114</b> is typically an elongated hollow instrument having at least one lumen <b>123</b>. The primary balloon <b>156</b> is shown engaged in direct contact with a body lumen <b>152</b> (e.g. a pulmonary vein). A sheath <b>116</b> is partially disposed about the primary balloon member <b>156</b> for providing irrigation (via conduit <b>120</b>) to the body lumen. Primary balloon member <b>156</b> and sheath <b>16</b> form the inner and outer membranes of the present invention.
In FIG. 10, the balloon catheter of FIG. 9 is shown in use. Fluid <b>117</b>, introduced between the inner membrane formed by the primary balloon member <b>156</b> and the outer membrane formed by sheath <b>116</b>, provides irrigation to an inner body lumen region <b>126</b>. The fluid <b>117</b> can be any physiologically compatible fluid, such as saline. Once the fluid <b>117</b> is introduced into the lumen region <b>126</b>, any blood or other substance remaining in the region is flushed out.
Another embodiment of balloon catheter <b>150</b> is shown in FIG. 11 having two conduits <b>120</b> and <b>124</b> within the catheter <b>114</b>. Conduit <b>120</b> provides irrigation fluid, such as saline, to the sheath <b>116</b>. Conduit <b>124</b> provides inflation fluid, such as deuterium oxide (D<sub>2</sub>O), to the primary balloon member <b>156</b>.
FIG. 12 illustrates another embodiment of the balloon catheter of the present invention. The opening <b>122</b> of the sheath <b>116</b> is positioned to deliver fluid <b>117</b> to the target ablation site <b>112</b>. This approach allows the fluid to contact the ablation site, thereby cooling the tissue to prevent over-heating or coagulation.
FIG. 13 illustrates another embodiment of the balloon catheter of the present invention. The sheath <b>116</b> contains pores <b>119</b> for releasing fluid near or at the target ablation site <b>112</b>. One having ordinary skill in the art will readily appreciate that the pores can be any shape or size. In addition, the sheath <b>116</b> can be sealed on both ends.
A person having ordinary skill in the art will readily appreciate that the size, quantity, and placement of the pores <b>119</b>, and the position of the sheath opening <b>122</b> can be used in conjunction with one another to provide a desired amount of fluid to the treatment site.
In another embodiment, the primary balloon <b>156</b> is preshaped to form a parabolic like shape. This is accomplished by shaping and melting a TEFLON® film in a preshaped mold to effect the desired form. The primary balloon <b>156</b> and sheath <b>116</b> of the present invention are preferably made of thin wall polyethylene teraphthalate (PET). The thickness of the membranes is preferably 5-50 micrometers, and more preferable, 10-20 micrometers. When inflated, the diameter of the membranes is preferably in the range of 20-30 millimeters.
The infrared radiation distributing devices of the present invention can be used for a variety of procedures, including laparoscopic, endoluminal, perivisceral, endoscopic, thoracoscopic, intra-articular and hybrid approaches. For example, atrial therapies can be performed by inserting an apparatus of the invention into the femoral vein. The catheter <b>114</b> having inner and outer membranes, e.g. primary balloon <b>156</b> and sheath <b>116</b>, fixedly attached thereto is guided through the inferior vena cava, and into the right atrium, and if required, it is guided into the left atrium via atrial septal puncture. Left ventricular treatment can be performed by inserting flexible elongate member <b>132</b> into the femoral artery. The catheter <b>114</b> is guided through the iliac artery, the aorta, through the aortic valve and into adjacent to the left ventricle. Once the primary balloon <b>156</b> is proximate to the tissue ablation site, a solution can be injected through lumen <b>120</b> into the sheath <b>116</b> to force blood and/or body fluids away from the treatment site. An optical apparatus is then guided through catheter <b>114</b> to a position proximate to the tissue ablation site <b>112</b> and energy, e.g., laser energy, is emitted through primary balloon <b>156</b>. Preferably, the composition of the primary balloon member <b>156</b> is transparent to the energy emitted through optical apparatus.
The primary balloon and sheath can be deflated by applying a vacuum that removes the fluid from the balloon. A syringe or other known methods can be used to remove the fluid. Once the primary balloon and sheath are fully deflated, the catheter can be easily removed from the body lumen.
Preferred energy sources for use with the hand held cardiac ablation instrument <b>10</b> and the balloon catheter <b>150</b> of the present invention include laser light in the range between about 200 nanometers and 2.5 micrometers. In particular, wavelengths that correspond to, or are near, water absorption peaks are often preferred. Such wavelengths include those between about 805 nm and about 1060 nm, preferably between about 900 nm and 1000 nm, most preferably, between about 915 nm and 980 nm. In a preferred embodiment, wavelengths around 915 nm are used during epicardial procedures, and wavelengths around 980 nm are used during endocardial procedures. Suitable lasers include excimer lasers, gas lasers, solid state lasers and laser diodes. One preferred AlGaAs diode array, manufactured by Optopower, Tucson, Ariz., produces a wavelength of 980 nm. Typically the light diffusing element emits between about 2 to about 10 watts/cm of length, preferably between about 3 to about 6 watts/cm, most preferably about 4 watts/cm.
The term “penetrating energy” as used herein is intended to encompass energy sources that do not rely primarily on conductive or convective heat transfer. Such sources include, but are not limited to, acoustic and electromagnetic radiation sources and, more specifically, include microwave, x-ray, gamma-ray, and radiant light sources.
The term “curvilinear,” including derivatives thereof, is herein intended to mean a path or line which forms an outer border or perimeter that either partially or completely surrounds a region of tissue, or separate one region of tissue from another. Further, a “circumferential” path or element may include one or more of several shapes, and may be for example, circular, annular, oblong, ovular, elliptical, or toroidal. The term “clasp” is intended to encompass various types of fastening mechanisms including sutures and magnetic connectors as well as mechanical devices. The term “light” is intended to encompass radiant energy, whether or not visible, including ultraviolet, visible and infrared radiation.
The term “lumen,” including derivatives thereof, is herein intended to mean any cavity or lumen within the body which is defined at least in part by a tissue wall. For example, cardiac chambers, the uterus, the regions of the gastrointestinal tract, the urinary tract, and the arterial or venous vessels are all considered illustrative examples of body spaces within the intended meaning.
The term “catheter” as used herein is intended to encompass any hollow instrument capable of penetrating body tissue or interstitial cavities and providing a conduit for selectively injecting a solution or gas, including without limitation, venous and arterial conduits of various sizes and shapes, bronchioscopes, endoscopes, cystoscopes, culpascopes, colonscopes, trocars, laparoscopes and the like. Catheters of the present invention can be constructed with biocompatible materials known to those skilled in the art such as those listed supra, e.g., silastic, polyethylene, Teflon, polyurethanes, etc.
It should be understood that the term “balloon” encompasses deformable hollow shapes which can be inflated into various configurations including balloon, circular, tear drop, etc., shapes dependent upon the requirements of the body cavity.
The term “transparent” is well recognized in the art and is intended to include those materials which allow transmission of energy through, for example, the primary balloon member. Preferred transparent materials do not significantly impede (e.g., result in losses of over 20 percent of energy transmitted) the energy being transferred from an energy emitter to the tissue or cell site. Suitable transparent materials include fluoropolymers, for example, fluorinated ethylene propylene (FEP), perfluoroalkoxy resin (PFA), polytetrafluoroethylene (PTFE), and ethylene-tetrafluoroethylene (ETFE).
One skilled in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety.
Contents5
16 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US10278849B2 | Cited by | United States of America | Applicant |
| WO2007109204A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| US2005209589A1 | Cited by | United States of America | Pre-grant |
| US11779195B2 | Cited by | United States of America | Applicant |
| US10441136B2 | Cited by | United States of America | Applicant |
| US8500730B2 | Cited by | United States of America | Applicant |
| US10390685B2 | Cited by | United States of America | Applicant |
| US11882996B2 | Cited by | United States of America | Applicant |
| US10695080B2 | Cited by | United States of America | Applicant |
| US11020136B2 | Cited by | United States of America | Applicant |
| US11207087B2 | Cited by | United States of America | Applicant |
| WO2007145820A1 | Cited by | World Intellectual Property Organization (WIPO) | Applicant |
| US7163534B2 | Cited by | United States of America | Applicant |
| US2016022358A1 | Cited by | United States of America | Pre-grant |
| US9629684B2 | Cited by | United States of America | Applicant |
| US11019989B2 | Cited by | United States of America | Applicant |
| US7344543B2 | Cited by | United States of America | Search report |
| US10772492B2 | Cited by | United States of America | Applicant |
| US2005234437A1 | Cited by | United States of America | Pre-grant |
| US2007073281A1 | Cited by | United States of America | Pre-grant |
| US2005096643A1 | Cited by | United States of America | Pre-grant |
| US9561074B2 | Cited by | United States of America | Search report |
| US2012310310A1 | Cited by | United States of America | Pre-grant |
| US9795442B2 | Cited by | United States of America | Applicant |
| US9814522B2 | Cited by | United States of America | Applicant |
| US11419487B2 | Cited by | United States of America | Applicant |
| US11337594B2 | Cited by | United States of America | Applicant |
| US2005143722A1 | Cited by | United States of America | Pre-grant |
| US9629656B2 | Cited by | United States of America | Applicant |
| US2009005768A1 | Cited by | United States of America | Pre-grant |
| US10251700B2 | Cited by | United States of America | Applicant |
| US9636258B2 | Cited by | United States of America | Applicant |
| US9820688B2 | Cited by | United States of America | Applicant |
| US11406250B2 | Cited by | United States of America | Applicant |
| US10813681B2 | Cited by | United States of America | Applicant |
| US9610006B2 | Cited by | United States of America | Applicant |
| US9750401B2 | Cited by | United States of America | Applicant |
| US10349824B2 | Cited by | United States of America | Applicant |
| US2005267452A1 | Cited by | United States of America | Pre-grant |
| US10463237B2 | Cited by | United States of America | Applicant |
| US10500380B2 | Cited by | United States of America | Applicant |
| US10524869B2 | Cited by | United States of America | Applicant |
| US9999752B2 | Cited by | United States of America | Applicant |
| US2009131931A1 | Cited by | United States of America | Pre-grant |
| US9603506B2 | Cited by | United States of America | Applicant |
| US10624695B2 | Cited by | United States of America | Applicant |
| US10492810B2 | Cited by | United States of America | Applicant |
| US2005234436A1 | Cited by | United States of America | Pre-grant |
| US9554708B2 | Cited by | United States of America | Applicant |
| US11684415B2 | Cited by | United States of America | Applicant |
| US2008119694A1 | Cited by | United States of America | Pre-grant |
| US7137977B2 | Cited by | United States of America | Applicant |
| US10575719B2 | Cited by | United States of America | Applicant |
| US10779752B2 | Cited by | United States of America | Applicant |
| US11832878B2 | Cited by | United States of America | Applicant |
| US2009171337A1 | Cited by | United States of America | Pre-grant |
| US7824402B2 | Cited by | United States of America | Search report |
| US2004167503A1 | Cited by | United States of America | Pre-grant |
| US2006200119A1 | Cited by | United States of America | Pre-grant |
| US10716629B2 | Cited by | United States of America | Applicant |
| US8986298B2 | Cited by | United States of America | Applicant |
| US7169142B2 | Cited by | United States of America | Applicant |
| US10874838B2 | Cited by | United States of America | Applicant |
| US10188413B1 | Cited by | United States of America | Applicant |
| US11350815B2 | Cited by | United States of America | Applicant |
| US11529502B2 | Cited by | United States of America | Applicant |
| US2005159734A1 | Cited by | United States of America | Pre-grant |
| US11478152B2 | Cited by | United States of America | Applicant |
| US10034682B2 | Cited by | United States of America | Applicant |
| US10265123B2 | Cited by | United States of America | Applicant |
| US2005222557A1 | Cited by | United States of America | Pre-grant |
| US11950838B2 | Cited by | United States of America | Applicant |
| US11957318B2 | Cited by | United States of America | Applicant |
| US2006253025A1 | Cited by | United States of America | Pre-grant |
| US10856927B2 | Cited by | United States of America | Applicant |
| US11511090B2 | Cited by | United States of America | Applicant |
| US2006084960A1 | Cited by | United States of America | Pre-grant |
| US11116392B2 | Cited by | United States of America | Applicant |
| US2007208329A1 | Cited by | United States of America | Pre-grant |
| US2007073278A1 | Cited by | United States of America | Pre-grant |
| US7207984B2 | Cited by | United States of America | Applicant |
| US11864725B2 | Cited by | United States of America | Applicant |
| US2005033287A1 | Cited by | United States of America | Pre-grant |
| US10806477B2 | Cited by | United States of America | Applicant |
| US10098694B2 | Cited by | United States of America | Applicant |
| US11153696B2 | Cited by | United States of America | Applicant |
| US10092172B2 | Cited by | United States of America | Applicant |
| US11246476B2 | Cited by | United States of America | Applicant |
| US2005171521A1 | Cited by | United States of America | Pre-grant |
| US10702295B2 | Cited by | United States of America | Applicant |
| US11241325B2 | Cited by | United States of America | Applicant |
| US11344365B2 | Cited by | United States of America | Applicant |
| US9826999B2 | Cited by | United States of America | Applicant |
| WO2009085653A1 | Cited by | World Intellectual Property Organization (WIPO) | Search report |
| US11439298B2 | Cited by | United States of America | Applicant |
| US11503991B2 | Cited by | United States of America | Applicant |
| US10470643B2 | Cited by | United States of America | Applicant |
| US7238179B2 | Cited by | United States of America | Search report |
| US10842978B2 | Cited by | United States of America | Applicant |
| US9717557B2 | Cited by | United States of America | Applicant |
118 members in 11 offices
Priority claims26
| Document | Office | Kind | Date |
|---|---|---|---|
| 30360594 | United States of America | A | |
| 30360594 | United States of America | A | |
| 82763197 | United States of America | A | |
| 82763197 | United States of America | A | |
| 99113097 | United States of America | A | |
| 99113097 | United States of America | A | |
| 39096499 | United States of America | A | |
| 39096499 | United States of America | A | |
| 61677700 | United States of America | A | |
| 61677700 | United States of America | A | |
| 0122299 | United States of America | W | |
| 0122299 | United States of America | W | |
| 92439401 | United States of America | A | |
| 08303605 | – | – | – |
| 08827631 | – | – | – |
| 08991130 | – | – | – |
| 09390964 | – | – | – |
| 09616777 | – | – | – |
| PCTUS0122299 | – | – | – |
| US19940303605 | – | – | – |
| US19970827631 | – | – | – |
| US19970991130 | – | – | – |
| US19990390964 | – | – | – |
| US20000616777 | – | – | – |
| US20010924394 | – | – | – |
| WO2001US22299 | – | – | – |
Members118
| Document | Office | Kind | |
|---|---|---|---|
| CA2199384A1 | Canada | A1 | |
| WO9607451A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3626995A | Australia | A | |
| WO9607451A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US5632767A | United States of America | A | |
| US5637877A | United States of America | A | |
| US5643253A | United States of America | A | |
| EP0781154A2 | European Patent Office (EPO) | A2 | |
| KR970706039A | Republic of Korea | A | |
| CN1165485A | China | A | |
| JPH10504989A | Japan | A | |
| US5908415A | United States of America | A | |
| US5947959A | United States of America | A | |
| US6102905A | United States of America | A | |
| AU725320B2 | Australia | B2 | |
| US6168591B1 | United States of America | B1 | |
| WO0103599A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU6215100A | Australia | A | |
| WO0113812A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7076200A | Australia | A | |
| WO0103599A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO0103599A9 | World Intellectual Property Organization (WIPO) | A9 | |
| US6270492B1 | United States of America | B1 | |
| CN1072971C | China | C | |
| CA2416242A1 | Canada | A1 | |
| WO0205722A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7593801A | Australia | A | |
| EP1200002A2 | European Patent Office (EPO) | A2 | |
| US2002068924A1 | United States of America | A1 | |
| US2002077623A1 | United States of America | A1 | |
| US6423055B1 | United States of America | B1 | |
| US2002183729A1 | United States of America | A1 | |
| EP1301139A1 | European Patent Office (EPO) | A1 | |
| US6558375B1 | United States of America | B1 | |
| US6572609B1 | United States of America | B1 | |
| JP2003518395A | Japan | A | |
| US6579285B2This record | United States of America | B2 | |
| US6626900B1 | United States of America | B1 | |
| US2004006333A1 | United States of America | A1 | |
| US6676656B2 | United States of America | B2 | |
| JP2004503326A | Japan | A | |
| US2004059397A1 | United States of America | A1 | |
| US2004147911A1 | United States of America | A1 | |
| US2004147912A1 | United States of America | A1 | |
| US2004147913A1 | United States of America | A1 | |
| AU2004208838A1 | Australia | A1 | |
| AU2004208838A2 | Australia | A2 | |
| CA2515029A1 | Canada | A1 | |
| WO2004069072A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2004167503A1 | United States of America | A1 | |
| WO2004069072A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2004110258A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2005038419A9 | United States of America | A9 | |
| US2005065504A1 | United States of America | A1 | |
| EP1527798A2 | European Patent Office (EPO) | A2 | |
| JP3675482B2 | Japan | B2 | |
| US2005171520A1 | United States of America | A1 | |
| WO2004110258A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US6942657B2 | United States of America | B2 | |
| US2005222557A1 | United States of America | A1 | |
| US2005222558A1 | United States of America | A1 | |
| US6953457B2 | United States of America | B2 | |
| US2005234436A1 | United States of America | A1 | |
| US2005234437A1 | United States of America | A1 | |
| EP1592358A2 | European Patent Office (EPO) | A2 | |
| US2005267452A1 | United States of America | A1 | |
| EP1200002B1 | European Patent Office (EPO) | B1 | |
| AT322870T | Austria | T | |
| DE60027300D1 | Germany | D1 | |
| CA2199384C | Canada | C | |
| JP2006516465A | Japan | A | |
| EP1679045A2 | European Patent Office (EPO) | A2 | |
| WO2006091597A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2006253113A1 | United States of America | A1 | |
| DE60027300T2 | Germany | T2 | |
| EP1527798A3 | European Patent Office (EPO) | A3 | |
| US2007078451A1 | United States of America | A1 | |
| US7207984B2 | United States of America | B2 | |
| EP1866019A1 | European Patent Office (EPO) | A1 | |
| US7357796B2 | United States of America | B2 | |
| JP2008531086A | Japan | A | |
| US2008195088A1 | United States of America | A1 | |
| JP4261101B2 | Japan | B2 | |
| US2009221997A1 | United States of America | A1 | |
| EP1679045A3 | European Patent Office (EPO) | A3 | |
| US2009275934A1 | United States of America | A1 | |
| US2009299354A1 | United States of America | A1 | |
| US2009326320A1 | United States of America | A1 | |
| WO2010120881A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2010120883A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2010120881A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2010120883A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US7935108B2 | United States of America | B2 | |
| JP4732330B2 | Japan | B2 | |
| US8025661B2 | United States of America | B2 | |
| US2011245822A1 | United States of America | A1 | |
| US2011245828A1 | United States of America | A1 | |
| US8152795B2 | United States of America | B2 | |
| US2012116353A1 | United States of America | A1 | |
| US8231613B2 | United States of America | B2 |
40 transactions on the USPTO file
Allowed after 1 non-final rejection.
- Non-final rejections
- 1
- Final rejections
- 0
- RCEs
- 0
- Appeals
- 0
Over time
Point at a mark for the transactionTransactions
| Event | |
|---|---|
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | |
| Change in Power of Attorney (May Include Associate POA) | |
| Correspondence Address Change | |
| Entity status set to undiscounted (initial default setting or status change) | |
| Recordation of Patent Grant Mailed | |
| Patent Issue Date Used in PTA CalculationAllowed | |
| Issue Notification MailedAllowed | |
| Receipt into Pubs | |
| Application Is Considered Ready for Issue | |
| Issue Fee Payment Verified | |
| Workflow - Drawings Finished | |
| Workflow - Drawings Matched with File at Contractor | |
| Workflow - Drawings Received at Contractor | |
| Workflow - Drawings Sent to Contractor | |
| Issue Fee Payment Received | |
| Receipt into Pubs | |
| Mailing Corrected Notice of Allowability | |
| Corrected Notice of Allowability | |
| Workflow - Customer Service Request - Finish | |
| Workflow - Customer Service Request - Begin | |
| Receipt into Pubs | |
| Workflow - File Sent to Contractor | |
| Receipt into Pubs | |
| Dispatch to Publications | |
| Mail Notice of AllowanceAllowed | |
| Notice of Allowance Data Verification CompletedAllowed | |
| Date Forwarded to Examiner | |
| Response after Non-Final Action | |
| Interview Summary Record | |
| Mail Non-Final RejectionNon-final rejection | |
| Non-Final RejectionNon-final rejection | |
| Case Docketed to Examiner in GAU | |
| Application Dispatched from OIPE | |
| Application Is Now Complete | |
| Payment of additional filing fee/Preexam | |
| A statement by one or more inventors satisfying the requirement under 35 USC 115, Oath of the Applic | |
| Notice Mailed--Application Incomplete--Filing Date Assigned | |
| Correspondence Address Change | |
| IFW Scan & PACR Auto Security Review | |
| Initial Exam Team nn |
21 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| AssignmentAS | AS | |
| AssignmentAS | AS | |
| Fee paymentFPAY | FPAY | |
| AssignmentAS | AS | |
| AssignmentAS | AS | |
| Fee paymentFPAY | FPAY | |
| Surcharge for late paymentSULP | SULP | |
| Maintenance fee reminder mailedREMI | REMI | |
| Fee payment procedureFEPP | FEPP | |
| Fee payment procedureFEPP | FEPP | |
| Fee payment procedureFEPP | FEPP | |
| AssignmentAS | AS | |
| Fee paymentFPAY | FPAY | |
| Fee payment procedureFEPP | FEPP | |
| RefundREFU | REFU | |
| AssignmentAS | AS | |
| AssignmentAS | AS | |
| Information on status: patent grantGrantedSTCF | STCF | |
| AssignmentAS | AS | |
| Fee payment procedureFEPP | FEPP | |
| AssignmentAS | AS |
Numbers
- Publication, DOCDB
- 6579285
- Publication, EPODOC
- US6579285
- Application
- 9924394
- Application, DOCDB
- 92439401
- Application, EPODOC
- US20010924394
Titles
- English
- Photoablation with infrared radiation
Patent term adjustment
- A delay
- +4 daysthe office missed an examination deadline
- Applicant delay
- −131 days
- Net adjustment
- 0 days
Classification
- CPC, 10
- A61B18/22
- A61B2017/00243
- A61B2018/2261
- A61B2018/2272
- A61B2018/2288
- A61L2/10
- A61L29/085
- A61N5/0601
- A61B2018/00351
- A61B2018/00577
- IPC, 5
- A61B17 00
- A61B18 22
- A61L2 10
- A61L29 08
- A61N5 06
- USPC, 2
- 606016000
- 128898000